Georges Joseph, MD
Interventional Cardiology · Weeki Wachee, FLNPI 1548555956
Payments from drug & device makers
Across 380 payments — averaging $40.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abbott$3K
- Medtronic$2K
- Abiomed$1K
- Edwards Lifesciences$984
- Inari Medical, Inc.$771
- plus $5K from 30 others
What the payments were for
- Travel & lodging$1,2268%
- Food & beverage$14,22592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 77 | $2,928 |
| Abbott | 45 | $2,656 |
| Medtronic(2 entities) | 56 | $2,489 |
| Abiomed | 17 | $1,095 |
| Edwards Lifesciences | 11 | $984 |
| Inari Medical, Inc. | 11 | $771 |
| Boehringer Ingelheim | 18 | $674 |
| Cardiovascular Systems Inc. | 4 | $597 |
| AstraZeneca | 18 | $486 |
| Johnson & Johnson | 26 | $394 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $342 |
| Amgen | 18 | $315 |
| Esperion Therapeutics, Inc. | 11 | $230 |
| Pfizer | 10 | $209 |
| Bayer | 3 | $146 |
| Lexicon Pharmaceuticals, Inc. | 2 | $146 |
| Atricure, Inc. | 1 | $136 |
| Corcept Therapeutics | 1 | $102 |
| Novartis | 5 | $80 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $69 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $59 |
| Cardiva Medical, Inc. | 1 | $49 |
| Kestra Medical Technology Services, Inc. | 2 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Elutia, Inc. | 2 | $34 |
| Merck | 2 | $34 |
| Stryker | 1 | $32 |
| Scpharmaceuticals Inc. | 1 | $31 |
| Astellas Pharma US Inc | 2 | $30 |
| Cleerly, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $16 |
| Cardinal Health 200 LLC | 1 | $13 |
| Biosense Webster, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUX-Dx Insertable Cardiac Monitor$867
- FLOWTRIEVER CATHETER, S$633
- CT THROMBECTOMY SYSTEM KIT$633
- Edwards SAPIEN 3 Transcatheter Heart Valve$550
- Peripheral Orbital Atherectomy System$495
- Micra$406
- AVEIR$393
- Impella$392
- JARDIANCE$362
- NAVITOR$331
- COREVALVE EVOLUT R$315
- CARDIOMEMS$313
- Reveal LINQ$285
- Xience Sierra Coronary Stent System$272
- Quadra Assura CRT Defibrillator$249
- LINQ II$247
- LifeVest$223
- SYMPLICITY G3$171
- Assurity Pacemaker$160
- CoreValve Evolut$151
How this compares
$15,451 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 371 | $499,718 |
| XareltoRivaroxaban | 94 | $123,968 |
| EntrestoSacubitril/Valsartan | 65 | $84,341 |
| Repatha SureclickEvolocumab | 50 | $52,677 |
| FarxigaDapagliflozin Propanediol | 38 | $50,701 |
| BrilintaTicagrelor | 59 | $43,093 |
| JardianceEmpagliflozin | 24 | $22,218 |
| VascepaIcosapent Ethyl | 23 | $18,262 |
| Metoprolol Succinate | 1,004 | $14,524 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 32 | $11,699 |
| Ranolazine ErRanolazine | 39 | $10,326 |
| ClopidogrelClopidogrel Bisulfate | 534 | $9,119 |
| Prasugrel Hcl | 12 | $5,799 |
| Midodrine Hcl | 50 | $5,514 |
| Nitroglycerin | 148 | $5,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $209 | $499,718371 claims |
| Johnson & JohnsonXarelto | $394 | $123,96894 claims |
| AstraZenecaFarxiga, Brilinta | $486 | $93,79497 claims |
| NovartisEntresto | $80 | $84,34165 claims |
| Boehringer IngelheimJardiance | $674 | $22,21824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Weeki Wachee
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.